Heparin Sodium Wockhardt Uk

Heparin Sodium Wockhardt Uk is an injectable anticoagulant containing the active ingredient heparin sodium; the specific strength is not disclosed, and it is supplied as a sterile solution for intravenous administration. Marketed in the European Union, this prescription‑only product belongs to the antithrombotic therapeutic class and works by enhancing antithrombin III activity to inhibit clot‑forming factors. It is intended for use under medical supervision in hospital or clinical settings.

Heparin Sodium Wockhardt Uk is employed in clinical practice for several antithrombotic indications where rapid anticoagulation is required.

- Prevention of venous thromboembolism (VTE) in patients undergoing major surgery or immobilization. - Treatment of acute deep‑vein thrombosis (DVT) to limit clot extension. - Management of pulmonary embolism (PE) as part of an initial anticoagulant regimen. - Prophylaxis of clot formation during cardiac or vascular procedures that involve extracorporeal circulation. - Use in heparin‑induced thrombocytopenia (HIT) testing protocols as a reference anticoagulant.

Adverse reactions to Heparin Sodium Wockhardt Uk are reported across a range of frequencies and may involve hematologic, allergic, or systemic manifestations.

Common: - Minor bleeding at the injection site or bruising. - Transient elevation of liver enzymes without clinical symptoms. - Mild thrombocytopenia that resolves with continued therapy.

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis. - Allergic reactions such as urticaria, angioedema, or anaphylaxis.

When prescribing Heparin Sodium Wockhardt Uk, clinicians should observe several precautionary measures to minimize risk and ensure safe use.

- Assess baseline coagulation parameters and platelet count before initiation. - Adjust dose in patients with renal or hepatic impairment, as drug clearance may be altered. - Monitor activated partial thromboplastin time (aPTT) regularly to maintain therapeutic range. - Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products. - Consider alternative anticoagulation in pregnant patients unless benefits outweigh potential risks. - Discontinue promptly if signs of HIT or uncontrolled bleeding develop.

Heparin Sodium Wockhardt Uk can interact with other medicines that affect hemostasis or share metabolic pathways, requiring careful management.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) that may amplify bleeding risk. - Administration of thrombolytic agents such as alteplase or streptokinase, which can lead to severe hemorrhage.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) and antiplatelet agents (e.g., aspirin, clopidogrel) may increase minor bleeding. - High‑dose corticosteroids can potentiate anticoagulant effect. - Certain antibiotics (e.g., quinolones) have been associated with platelet dysfunction when combined with heparin.